Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C W135 and Y polysaccharide - Pfizer

Drug Profile

Meningococcal vaccine groups A C W135 and Y polysaccharide - Pfizer

Alternative Names: ACWY Vax; Mencevax ACWY

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 01 Oct 2015 Pfizer acquires meningococcal vaccine groups A, C, W135 and Y polysaccharide from GlaxoSmithKline
  • 22 Jun 2015 Pfizer enters into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, including Mencevax vaccine ,
  • 22 Jun 2015 Registered for Meningococcal infections (In adolescents, In adults, In children, Prevention) in Middle East, Latin America, Europe, Australia, Africa, Asia (SC) before June 2015
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top